HORIZON THERAPEUTICS PLC (HZNP) Stock Analyst Ratings
USA - NASDAQ:HZNP - IE00BQPVQZ61 - Common Stock
116.3 USD
+0.05 (+0.04%)
116.34 USD
+0.04 (+0.03%)
ChartMill assigns a Buy % Consensus number of 51% to HZNP. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 118.83. This target is 2.18% above the current price.
HZNP was analyzed by 11 analysts. The buy percentage consensus is at 51. So analysts seem to be rather neutral about HZNP.
In the last month the buy percentage fell by 24 points. So the trust of analysts is decreasing.
HZNP was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-12-13 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-12-13 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2022-12-13 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-12-13 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2022-12-12 | Stifel | Downgrade | Buy -> Hold |
| 2022-12-07 | Piper Sandler | Maintains | Overweight |
| 2022-11-03 | SVB Leerink | Maintains | Outperform |
| 2022-11-01 | HC Wainwright & Co. | Initiate | Neutral |
| 2022-10-25 | Piper Sandler | Maintains | Overweight |
| 2022-08-04 | BMO Capital | Maintains | Outperform |
| 2022-08-04 | UBS | Downgrade | Buy -> Neutral |
| 2022-08-04 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2022-08-04 | Goldman Sachs | Maintains | Buy |
| 2022-08-04 | Morgan Stanley | Maintains | Overweight |
| 2022-07-05 | UBS | Maintains | Buy |
| 2022-06-14 | UBS | Initiate | Buy |
| 2022-05-24 | SVB Leerink | Initiate | Market Perform |
| 2022-05-23 | SVB Leerink | Initiate | Market Perform |
| 2022-05-05 | Morgan Stanley | Maintains | Overweight |
| 2022-03-02 | Morgan Stanley | Maintains | Overweight |
| 2021-12-08 | Wells Fargo | Initiate | Overweight |
| 2021-11-19 | Goldman Sachs | Upgrade | Neutral -> Buy |
| 2021-08-26 | Morgan Stanley | Maintains | Overweight |
| 2021-08-24 | Goldman Sachs | Maintains | Neutral |
| 2021-08-05 | BMO Capital | Maintains | Outperform |
| 2021-08-05 | Citigroup | Maintains | Buy |
| 2021-03-22 | Morgan Stanley | Reiterate | Overweight |
| 2021-03-18 | Citigroup | Maintains | Buy |
| 2021-03-17 | Stifel | Maintains | Buy |
| 2021-03-12 | Wolfe Research | Initiate | Outperform |
HORIZON THERAPEUTICS PLC / HZNP FAQ
What is the price target for HZNP stock?
11 analysts have analysed HZNP and the average price target is 118.83 USD. This implies a price increase of 2.18% is expected in the next year compared to the current price of 116.3.
What is the consensus rating for HORIZON THERAPEUTICS PLC (HZNP) stock?
The consensus rating for HORIZON THERAPEUTICS PLC (HZNP) is 50.9091 / 100 . This indicates that analysts generally have a neutral outlook on the stock.